505486 Pramipexole Dihydrochloride - CAS 104632-25-9 - Calbiochem

505486
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
Demander le prix
Disponibilité limitéeDisponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service
      Voir les Prix & la Disponibilité

      Aperçu

      Replacement Information

      Tableau de caractéristiques principal

      Empirical FormulaCAS #
      C₁₀H₁₇N₃S•2HCl 104632-25-9

      Prix & Disponibilité

      Référence DisponibilitéConditionnement Qté Prix Quantité
      5054860001
      Récupération des données relatives à la disponibilité...
      Disponibilité limitéeDisponibilité limitée
      En stock 
      Interrompu(e)
      Disponible en quantités limitées
      Disponibilité à confirmer
        Pour le restant : Nous vous tiendrons informé
          Pour le restant : Nous vous tiendrons informé
          Nous vous tiendrons informé
          Contacter le Service Clients
          Contact Customer Service

          Flacon en verre 10 mg
          Prix en cours de récupération
          Le prix n'a pas pu être récupéré
          La quantité minimale doit être un multiple de
          À la validation de la commande Plus d'informations
          Vous avez sauvegardé ()
           
          Demander le prix
          Description
          OverviewNon-ergot Dopamine receptor agonist with selectivity for the D3 receptor (Ki values are 0.5, 3.3, 3.9 and 3.9 nM for D3, D2S, D2L and D4 receptors respectively). Exhibits very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors, as well as D1-type receptors. Shows good solubility in aqueous media (100 mM water and 100 mM DMSO). Immediate-release (IR) pramipexole dihydrochloride is indicated for the treatment of signs and symptoms of idiopathic Parkinsons disease (PD). It is administered alone (without levodopa) or in combination with levodopa, during the entire progress of the disease, up to an advanced stage. Currently, it is also indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
          Catalogue Number505486
          Brand Family Calbiochem®
          SynonymsPramipexole, Dopamine D2-like Receptor Agonist, Pramipexole, Dopamine D3 Receptor Agonist, Pramipexole, (S)-Nʹ-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride
          References
          ReferencesAntonini, A. 2011. Expert Op. Drug Metabol. Tox. 7, 1307.
          Collins, G. T. et al. 2008. J. Pharmacol. 325, 691.
          Product Information
          CAS number104632-25-9
          FormWhite solid
          Hill FormulaC₁₀H₁₇N₃S•2HCl
          Chemical formulaC₁₀H₁₇N₃S•2HCl
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetD3
          Primary Target K<sub>i</sub>0.5 nM
          Purity≥99% by HPLC
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
          Toxicity Standard Handling
          Storage +2°C to +8°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Pramipexole Dihydrochloride - CAS 104632-25-9 - Calbiochem FDS

          Titre

          Fiche de données de sécurité des matériaux (FDS) 

          Références bibliographiques

          Aperçu de la référence bibliographique
          Antonini, A. 2011. Expert Op. Drug Metabol. Tox. 7, 1307.
          Collins, G. T. et al. 2008. J. Pharmacol. 325, 691.
          Fiche technique

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision30-August-2013 JSW
          SynonymsPramipexole, Dopamine D2-like Receptor Agonist, Pramipexole, Dopamine D3 Receptor Agonist, Pramipexole, (S)-Nʹ-Propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine dihydrochloride
          DescriptionNon-ergot Dopamine receptor agonist with selectivity for the D3 receptor (Ki values are 0.5, 3.3, 3.9 and 3.9 nM for D3, D2S, D2L and D4 receptors respectively). Exhibits very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors, as well as D1-type receptors. Shows good solubility in aqueous media (100 mM water and 100 mM DMSO). Immediate-release (IR) pramipexole dihydrochloride is indicated for the treatment of signs and symptoms of idiopathic Parkinsons disease (PD). It is administered alone (without levodopa) or in combination with levodopa, during the entire progress of the disease, up to an advanced stage. Currently, it is also indicated for the treatment of moderate-to-severe primary restless legs syndrome (RLS).
          FormWhite solid
          CAS number104632-25-9
          Chemical formulaC₁₀H₁₇N₃S•2HCl
          Structure formulaStructure formula
          Purity≥99% by HPLC
          SolubilityH₂O (100 mM)
          Storage +2°C to +8°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesAntonini, A. 2011. Expert Op. Drug Metabol. Tox. 7, 1307.
          Collins, G. T. et al. 2008. J. Pharmacol. 325, 691.